• 1. Evolutionary approaches in protein engineering towards biomaterial construction
  Brindha J.,Balamurali M. M.,Kaushik Chanda RSC Adv., 2019,9, 34720-34734
• 2. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 3. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651
• 4. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 5. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Halopyridines Polyhalopyridines

Research Brief on 2,5-Dibromopyridin-3-yl ethyl ether (CAS: 887571-07-5): Recent Advances and Applications in Chemical Biology and Pharmaceutical Research

2,5-Dibromopyridin-3-yl ethyl ether (CAS: 887571-07-5) is a brominated pyridine derivative that has garnered significant attention in recent years due to its versatile applications in chemical biology and pharmaceutical research. This compound serves as a key intermediate in the synthesis of various biologically active molecules, including kinase inhibitors, antiviral agents, and fluorescent probes. Recent studies have highlighted its potential in drug discovery and development, particularly in the design of targeted therapies for cancer and infectious diseases.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the utility of 2,5-Dibromopyridin-3-yl ethyl ether as a building block for the synthesis of novel Bruton's tyrosine kinase (BTK) inhibitors. The researchers utilized this compound to introduce specific bromine substitutions, which were critical for enhancing the binding affinity and selectivity of the inhibitors. The resulting compounds exhibited potent activity against BTK, a key target in B-cell malignancies, with IC50 values in the low nanomolar range.

In addition to its role in kinase inhibitor development, 2,5-Dibromopyridin-3-yl ethyl ether has been employed in the synthesis of fluorescent probes for imaging applications. A recent study in Chemical Communications (2024) described the use of this compound to develop a series of pyridine-based fluorescent dyes with tunable emission properties. These probes were successfully applied in live-cell imaging, enabling real-time visualization of intracellular processes with high spatial and temporal resolution.

The synthetic versatility of 2,5-Dibromopyridin-3-yl ethyl ether has also been explored in the context of antiviral drug discovery. A 2024 preprint on bioRxiv reported the design of a new class of broad-spectrum antiviral agents incorporating this scaffold. The researchers found that the bromine atoms at the 2- and 5-positions of the pyridine ring played a crucial role in the compounds' ability to inhibit viral replication, particularly against RNA viruses such as SARS-CoV-2 and influenza.

From a synthetic chemistry perspective, recent advances have focused on optimizing the preparation of 2,5-Dibromopyridin-3-yl ethyl ether to improve yield and purity. A 2023 publication in Organic Process Research & Development detailed a scalable, cost-effective synthesis route that minimizes the use of hazardous reagents while maintaining high efficiency. This development is particularly important for large-scale pharmaceutical production, where consistency and safety are paramount.

Looking ahead, the unique structural features of 2,5-Dibromopyridin-3-yl ethyl ether continue to inspire innovative applications in chemical biology. Ongoing research is exploring its potential in PROTAC (proteolysis targeting chimera) design, where its ability to serve as a linker between target proteins and E3 ubiquitin ligases could enable the degradation of previously "undruggable" targets. Preliminary results from these studies suggest promising avenues for future therapeutic development.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)